tb006
mAbexperimental
Clinical trial activity
8 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
5
Phase 3
0
Phase 4
0
Earliest trial started May 31, 2021 (NCT04801056)
Timeline
Indications
Mechanism of action
- Galectin-3ANTAGONIST
Galectin-3 antagonist
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06773962 | Phase 2 | Jan 24, 2025 | TrueBinding, Inc. |
| NCT06500637 | Phase 2 | Aug 3, 2024 | Rossignol Medical Center |
| NCT05476783 | Phase 2 | Sep 14, 2022 | TrueBinding, Inc. |
| NCT05156827 | Phase 2 | Feb 15, 2022 | TrueBinding, Inc. |
| NCT05074498 | Phase 1/Phase 2 (Phase 2) | Oct 8, 2021 | TrueBinding, Inc. |
| NCT04920786 | Phase 1 | Jun 1, 2021 | Collaborative Neuroscience Research, TrueBinding, Inc. |
| NCT04801056 | Phase 1 | May 31, 2021 | TrueBinding, Inc. |
| NCT05959239 | N/A | — | TrueBinding, Inc. |
Showing 8 of 8 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| TrueBinding, Inc. | For profit | 7 | 7 | 3 | 2021 |
| Collaborative Neuroscience Research | Academic/Hospital | 1 | 0 | 1 | 2021 |
| Rossignol Medical Center | Academic/Hospital | 1 | 1 | 1 | 2024 |
3 organizations
Page 1 / 1